J. Logue

Persistent immune imprinting after XBB.1.5 COVID vaccination in humans

This study shows that immune imprinting from prior Wuhan-Hu-1 spike exposure persists after XBB.1.5 vaccine booster, with neutralizing antibodies dominated by pre-existing memory B cells.

Full-spike deep mutational scanning helps predict the evolutionary success of SARS-CoV-2 clades

This study uses deep mutational scanning to assess how mutations in SARS-CoV-2 spike proteins affect ACE2 binding, cell entry, and serum escape, linking these effects to clade growth rates.

CNP blocks mitochondrial depolarization and inhibits SARS-CoV-2 replication in vitro and in vivo

This paper identifies CNP as a novel antiviral target that inhibits SARS-CoV-2 replication by blocking mitochondrial depolarization and mPTP activation in vitro and in vivo.

Diet Induced Obesity and Diabetes Enhance Mortality and Reduces Vaccine Efficacy for SARS-CoV-2

This study shows that obesity and diabetes increase SARS-CoV-2 mortality and reduce vaccine efficacy in mice, with neutrophil depletion improving outcomes.

Receptor binding domain (RBD) antibodies contribute more to SARS-CoV-2 neutralization when target cells express high levels of ACE2

This study shows that RBD antibodies contribute more to SARS-CoV-2 neutralization when target cells have high ACE2 expression, highlighting ACE2 levels as a critical experimental factor.

SIRT-1 is required for release of enveloped picornaviruses

This study shows SIRT-1 is essential for EV-D68 infection and enveloped virus release, independent of its deacetylase activity or autophagy.

Imprinted antibody responses against SARS-CoV-2 Omicron sublineages

This study shows that hybrid immunity and vaccine boosters provide potent neutralizing activity against Omicron BA.1 and BA.2, while breakthrough infections induce nasal mucosal neutralization and identify an ultrapotent pan-variant antibody.

Mucosal and systemic responses to SARS-CoV-2 vaccination in infection naive and experienced individuals

This study examines immune responses to SARS-CoV-2 vaccination in individuals with and without prior infection, finding higher antibody levels and neutralizing titers in previously infected individuals.

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

This study shows that Omicron variant's spike protein has enhanced ACE2 binding and reduces neutralizing activity, but some broadly neutralizing antibodies remain effective.

Delta breakthrough infections elicit potent, broad and durable neutralizing antibody responses

The paper examines antibody responses in Delta breakthrough infections, finding they are more potent, durable, and broad compared to vaccinated-only or infected-only individuals.

Self-assembling short immunostimulatory duplex RNAs with broad spectrum antiviral activity

This paper introduces self-assembling short duplex RNAs that induce interferon production and inhibit multiple respiratory viruses.

Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variants

This study investigates how delta and kappa SARS-CoV-2 variants evade immune responses by altering antigenic sites and reducing ACE2 binding affinity.

Immunogenicity and In vivo protection of a variant nanoparticle vaccine that confers broad protection against emerging SARS-CoV-2 variants

This study evaluates a nanoparticle vaccine against SARS-CoV-2 variants, showing it induces strong immune responses and protection in mice and baboons against multiple variants.

Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination

This study shows that NVX-CoV2373 vaccine induces antibodies with both neutralizing and Fc-effector functions, which together provide maximal protection against SARS-CoV-2 in non-human primates.

Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail

This paper determines the structures of two antibodies in the AZD7442 cocktail that neutralize SARS-CoV-2 and identifies critical residues for neutralization and viral escape.

Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms

This study evaluates the in vitro antiviral activity of three Ebola and Marburg virus inhibitors against SARS-CoV-2 and explores their potential mechanisms of action.

Single-cell profiling of Ebola virus infection in vivo reveals viral and host transcriptional dynamics

This study uses single-cell transcriptomics and protein profiling to analyze EBOV infection in rhesus monkeys, revealing changes in immune cell dynamics and viral/host gene expression.

Human organ chip-enabled pipeline to rapidly repurpose therapeutics during viral pandemics

This paper demonstrates the use of human organ chips to rapidly repurpose therapeutics for viral pandemics, identifying amodiaquine as a potential treatment for SARS-CoV-2.

Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo

This study evaluates 20 FDA-approved drugs for antiviral activity against SARS-CoV-2 and SARS-CoV, finding 17 inhibit SARS-CoV-2 at non-cytotoxic concentrations and two protect mice from SARS-CoV disease.